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The retinoblastoma protein (RB)–E2F1 pathway has a
central role in regulating the cell cycle. Several PAX
proteins (tissue-speciﬁc developmental regulators), includ-
ing PAX8, interact with the RB protein, and thus regulate
the cell cycle directly or indirectly. Here, we report that
PAX8 expression is frequent in renal cell carcinoma,
bladder, ovarian and thyroid cancer cell lines, and that
silencing of PAX8 in cancer cell lines leads to a striking
reduction in the expression of E2F1 and its target genes,
as well as a proteasome-dependent destabilization of RB
protein, with the RB1 mRNA level remaining unaffected.
Cancer cells expressing PAX8 undergo a G1/S arrest and
eventually senesce following PAX8 silencing. We demon-
strate that PAX8 transcriptionally regulates the E2F1
promoter directly, and E2F1 transcription is enhanced
after RB depletion. RB is recruited to the PAX8-binding
site, and is involved in PAX8-mediated E2F1 transcription
in cancer cells. Therefore, our results suggest that, in
cancer, frequent and persistent expression of PAX8 is
required for cell growth control through transcriptional
activation of E2F1 expression and upregulation of the
RB–E2F1 pathway.
Oncogene (2011) 30, 4824–4834; doi:10.1038/onc.2011.190;
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Introduction
PAX8 is a cell-lineage-speciﬁc transcription factor, best
characterized for its role in thyrocyte differentiation
through activation of thyroid differentiation markers:
thyroglobulin, thyroperoxidase and sodium/iodide sym-
porter (Zannini et al., 1992; Esposito et al., 1998; Fabbro
et al., 1998; Ohno et al., 1999). Pax8 homozygous null
mutant mice have congenitally smaller thyroids compared
with heterozygous mutant or wild-type littermates,
and suffer from hypothyroidism (Mansouri et al., 1998).
Similarly, in humans, heterozygous mutations of PAX8
are associated with congenital thyroid dysgenesis (Macchia
et al., 1998; Vilain et al., 2001).
During fetal development, Pax8 is also expressed in
three sites in addition to thyroid. Early in central
nervous system development, Pax8 is expressed in the
midbrain–hindbrain boundary (Stoykova and Gruss,
1994). Pax8 is also expressed during inner ear develop-
ment and in the cells of the pronephric, mesonephroic
and metanephric lineages (Plachov et al., 1990; Pfeffer
et al., 1998; Bouchard et al., 2002). Although Pax8
knockout mice have normal kidney development (Man-
souri et al., 1998), either a heterozygous or a homo-
zygous Pax8 null mutation together with a background
of a Pax2 heterozygous null mutation in mice results in
major loss, or complete depletion, respectively, of the
nephric cell lineage through increased apoptotic cell
death (Bouchard et al., 2002; Narlis et al., 2007). These
data suggest an early role for Pax8 together with Pax2 in
nephron lineage speciﬁcation and/or survival.
The cell cycle is the fundamental process controlling
cell proliferation. Emerging evidence has demonstrated
that the cell cycle also critically modulates cellular
differentiation. Cellular commitment to terminal differ-
entiation is accompanied by a permanent exit from
the cell cycle in the G1 phase (Buttitta and Edgar, 2007).
The retinoblastoma protein (RB)–E2F1 pathway is
central to the regulatory mechanism of cell-cycle
control, and deregulation of this pathway is one of the
key factors contributing to tumorigenesis. RB is best
characterized for its dual tumor-suppressor role; ﬁrst, by
negatively regulating the cell-cycle progression at the
G1/S transition by modulating the activity of E2F
transcription factors (Weinberg, 1995), and second, by
binding and modulating tissue-speciﬁc transcription
factors to promote terminal differentiation (Sellers
et al., 1998). Classically, RB binds to and inhibits E2F
transactivation activity (Flemington et al., 1993). Upon
phosphorylation by cyclin/cyclin-dependent kinase com-
plexes, RB dissociates from E2F, which then becomes
transcriptionally active in the late G1 phase (Chellappan
et al., 1991; Burkhart and Sage, 2008). RB also modu-
lates E2F activity by additionally recruiting chromatin
remodeling factors (Frolov and Dyson, 2004). RB
activity is regulated through post-translational modiﬁ-
cations, including phosphorylation (primarily), acetyla-
tion and methylation (Chan et al., 2001; Munro et al.,
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www.nature.com/onc2010). Although cellular RB expression is stable during
cell cycle and differentiation (Yen et al., 1997), it has
been shown to be targeted for proteasome-dependent
degradation by cellular and viral oncoproteins: gankyr-
in, MDM2, human parpaillovirus E7, Epstein-Barr
virus nuclear antigen-3C and human megalovirus pp71
protein (Boyer et al., 1996; Berezutskaya and Bagchi,
1997; Higashitsuji et al., 2000; Kalejta and Shenk, 2003;
Knight et al., 2005; Sdek et al., 2005), and only A-type
lamins have so far been identiﬁed to contribute to the
stability of RB protein (Nitta et al., 2006).
Unlike RB, E2F1 expression is strictly cell-cycle
dependent, and its protein is unstable owing to active
degradation through the ubiquitin–proteasome pathway
(Hofmann et al., 1996). Physical interaction between
E2F1 and hypophosphorylated RB has been shown to
be required for its protein stability (Hofmann et al.,
1996). Upon release from RB in the late G1 phase, E2F1
binds to and activates its own promoter, resulting in
accumulation of newly synthesized free E2F1, in order
to activate gene expression required for S-phase entry
(Johnson et al., 1994). E2F1 expression is subsequently
downregulated through suppression of E2F7–E2F8 on
the E2F1 promoter (Zalmas et al., 2008). Although
downstream target genes of E2F1 are well established,
relatively little is known about the upstream regulators
of the steady-state expression of E2F1. The Myc
oncoprotein is also thought to contribute to pre-S-phase
E2F1 expression through regulation of the E2F1
promoter (Fernandez et al., 2003; Leung et al., 2008).
PAX8 has emerged as a potential diagnostic marker
for ovarian carcinomas (Hibbs et al., 2004; Bowen et al.,
2007), renal cell carcinomas (RCCs) (Tong et al., 2009)
and pancreatic endocrine tumor (Long et al., 2010). In
addition, frequent expression of PAX8 has been
reported in Wilms tumor, thyroid carcinoma and
glioma. Little is known about the biological signiﬁcance
of PAX8 expression in cancer. Several observations
suggest that Pax8 could directly or indirectly inﬂuence
cell growth and survival; ﬁrst, inhibiting Pax8 expression
in a rat thyroid cell line caused growth reduction (Rossi
et al., 1995), suggesting that Pax8 inﬂuences cell
proliferation or survival. Second, Pax8 is one of the
tissue-speciﬁc factors that complexes with RB to
promote the expression of thyroid differentiation genes
in rat thyrocyte cells (Miccadei et al., 2005). Further-
more, we have shown previously that PAX8 positively
regulates the expression of telomerase RNA (hTR)a n d
telomerase reverse transcriptase (hTERT) in colorectal
and glioma cell lines (Chen et al., 2008), suggesting that
PAX8 expression could be critical for maintenance of
telomeres and immortalization.
The observation that PAX8 is required for the growth
and differentiation of several cell types suggests that
interaction between PAX8 and RB could likewise have an
important role in cell growth and differentiation. In spite
of signiﬁcant progress in recent years in understanding the
regulation of the cell cycle, it remains unclear as to how the
growth and differentiation of a tissue are coordinated
together with the regulation of the cell cycle in a tissue-
speciﬁc manner so as to facilitate terminal differentiation,
and in particular how this process is disrupted in cancer.
To determine whether PAX8 is a tissue-speciﬁc regulator
of cell proliferation and differentiation that becomes
dysregulated in cancer, we silenced PAX8 expression in
multiple cancer cell lines using small interfering RNAs
(siRNA). Silencing of PAX8 causes a reduction in E2F1
mRNA and protein levels in cancer cell lines, as well as a
reduction in the levels of E2F1 target genes, including
cyclin-A2 (CCNA2)a n dCDC6, induction of G1/S cell-
cycle arrest and onset of cellular senescence. We further
show that PAX8 binds to and transactivates the E2F1
promoter, and that PAX8 is also required for RB
stabilization, thereby forming a negative feedback loop,
which represses PAX8-mediated transactivation of the
E2F1 promoter. Our results therefore support the
hypothesis that PAX8 is important for cancer cell growth
and viability through regulation of key proteins involved
in cell-cycle control.
Results
PAX8 expression in human cancer cell lines
As indicated above, it has been reported that PAX8 is
expressed in subsets of normal adult renal tissue and
persistently expressed in dedifferentiated cells character-
izing RCCs (Tong et al., 2009). To conﬁrm this
observation, we performed immunohistochemical ana-
lysis of PAX8 expression on 10 RCC tumors and their
normal kidney counterparts. An example is shown in
Figure 1, which shows that PAX8 exhibits widespread
Figure 1 PAX8 is expressed in RCC and adult normal kidney tissues. PAX8 expression was analyzed in 10 RCC sections and their
normal kidney counterparts (cortex and medulla). Staining was consistently observed in the RCC cells, as well as in the cortex and
medulla of adult kidney. A representative set is presented here. Abbreviations: PCT, proximal convoluted tubule; DCT, distal
convoluted tubule; BC, Bowman’s capsule; CD, collecting duct; RCC, renal cell carcinoma; TNL, thin loop of Henle; TKL, thick loop
of Henle. Magniﬁcation:  40. The scale bar represents 50mm.
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Oncogeneexpression in RCC, as well as in speciﬁc regions of the
normal kidney, with strongest staining evident in the
thin loop of Henle, the distal convoluted tubules and the
collecting ducts, and weakest staining in the proximal
convoluted tubule. Next we assessed the generality of
PAX8 expression in cancer by determining PAX8
protein levels by immunoblotting (Figure 2a). High
levels of PAX8 were detected in RCCs, bladder
carcinomas, ovarian carcinomas and thyroid cancers.
Furthermore, PAX8 was also detected in two retino-
blastoma cell lines (Y79 and WERI-Rb), but undetect-
able in J82 bladder, MCF-7 breast, PC-3 prostate and
RKO colon cancer cell lines. Immunoblotting detected
multiple PAX8 bands in most cell lines. The multiple
bands were likely isoforms related to PAX8 (Poleev
et al., 1995), because PAX8 as well as the multiple bands
were silenced (Supplementary Figure S1A) when PAX8
was silenced using two PAX8 targeting siRNAs
(siPAX8-1 and siPAX8-2).
PAX8 silencing in cancer cells leads to growth retardation
and triggers senescence
To investigate whether PAX8 expression in the above
cancer cell lines confers a growth advantage, we initially
examined the effect of PAX8 knockdown on cell
viability using two RCC (A498 and 786-O), one ovarian
(IGROV-1) and one thyroid (K1) cancer cell line,
using the trypan blue exclusion assay. Cancer cell lines
transfected with PAX8 siRNAs showed severe growth
retardation following transfection, as compared with
siControl-transfected cells (Figure 2b) or untransfected
cells (IGROV-1 and K1). In addition, we observed
morphological changes of PAX8-deﬁcient cells using
phase-contrast microscopy. PAX8-depleted cells exhib-
ited an enlarged and ﬂattened morphology, demonstrat-
ing the typical phenotype of senescent cells (Figure 2c).
To conﬁrm that senescence was induced following
PAX8 silencing, we performed histochemical detection
of senescence-associated (SA) b-galactosidase (SA-b-
gal) activity, a widely used marker of senescence. Less
than 3.1% of the control cells were SA-b-gal positive,
but a marked increase of SA-b-gal-positive cells (70.3%)
was observed in K1 thyroid cancer cells following PAX8
siRNA transfection (Figure 2d). Similar results were
also observed in three additional cancer cell lines
(Supplementary Figure S1B), suggesting that the loss
of PAX8 expression induces senescence of cancer cells.
Silencing of PAX8 in cancer cells induces cell-cycle arrest
To determine whether silencing of PAX8 leads to
blockade of cell-cycle progression, ﬂow cytometry was
used to study cell-cycle proﬁles using two RCC cell lines,
A498 and 786-O. At 72h post siRNA transfection,
cells were pulse-labeled with 5-bromodeoxyuridine
(BrdU) before ﬂow cytometry. PAX8 silencing led to a
signiﬁcant increase in the number of cells in the G1
phase, together with a reduction of the number of cells
in the S-phase (Figure 3a). To further examine the effect
of PAX8 silencing on the cell cycle, 48h after transfec-
tion with PAX8 siRNA, when PAX8 was clearly
Figure 2 PAX8 is frequently expressed in cancer cell lines and is required for cancer cell growth. (a) Whole-cell lysates of 19 cancer cell
lines were subjected to immunoblotting using the indicated antibodies. (b) Cell viability assessment. The effect of PAX8 knockdown on
the viability of A498, 786-O, IGROV-1 and K1 cells was determined using trypan blue exclusion assay. (c, d) K1 cells were transfected
with the indicated siRNA. At 120h post transfection, cells were examined by (c) phase-contrast microscopy and (d) stained for
SA-b-gal activity. Total cell number and stained cell number were counted in a blind manner. The data are the means±s.e.m. of two
independent experiments. SA-b-gal, senescence-associated b-galactosidase; siRNA, small interfering RNA.
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Oncogenedepleted (Supplementary Figure S1A), cells were pulsed
for 15min with BrdU, and then incubated for a further
24h after which they were harvested and analyzed using
ﬂow cytometry (Figure 3b). Using this technique, we
predicted that we would be able to identify phases of the
cell cycle that were defective following PAX8 knock-
down. Consistent with the cell-cycle proﬁles, depletion
of PAX8 in the cancer cell lines resulted in a strikingly
decreased cell population entering the S-phase. For
example, in 786-O cells, upon PAX8 silencing, only
15.0±1.5% of the cells that had incorporated BrdU
progressed to S-phase, compared with the control
(53.3±3.2%; R2/R1; Figure 3c). Similar results were
observed with A498 cells (Figure 3c) and several other
cell lines derived from other cancer types (Supplemen-
tary Table S1). Thus, PAX8 silencing leads to an arrest
of cell-cycle progression at the G1/S phase border.
Collectively, these data suggest that PAX8 expression
could confer a growth advantage to cancer cells.
PAX8 binds to and is required for transactivating
E2F1 promoter activity
A preliminary microarray analysis was performed
to proﬁle gene expression changes following PAX8
silencing in A498 cells. To minimize off-target siRNA
effects, only genes with a greater than twofold change in
expression in common between two different siRNA
treatments using either siPAX8-1 or siPAX8-2 were
further analyzed. The array data were evaluated using
Gene Onotology and Ingenuity Pathway Analysis. The
analysis revealed downregulation of several cell-cycle
regulators following PAX8 silencing (data not shown).
Interestingly, E2F1, a key regulator of S-phase entry,
and many of its transcriptional targets were found to be
downregulated in PAX8 siRNA-transfected cells. We
then selected E2F1, CCNA2, CDC6, MCM3 and DHFR
for further validation using quantitative real time PCR
(qPCR) analysis. Consistent with preliminary microarray
data, validation using qPCR demonstrated a substantial
downregulation of these E2F1 targets following PAX8
knockdown (Figure 4a). In addition, we observed the
same altered gene expression pattern in the 786-O cells
(Figure 4a). Next, we conﬁrmed the expression changes
at the protein level using A498, 786-O, IGROV-1 and K1
cell lines, by immunoblotting using the indicated
antibodies. Corresponding to the qPCR data, both
E2F1 and cyclin-A proteins were markedly reduced in
siPAX8-transfected cells (Figure 4b). Similarly, CDC6
protein level was also reduced (Figure 4b). The data
obtained from both qPCR and immunoblotting show
that PAX8 knockdown leads to downregulation of
several E2F1 target genes.
As E2F1 gene expression, demonstrated above, was
nearly abolished upon PAX8 knockdown, we reasoned
that the E2F1 promoter activity could be sensitive to
PAX8 dosage. To investigate this possibility, we silenced
PAX8 expression transiently in K1 cells using siRNAs.
At 24h post siRNA transfection, we transfected a
luciferase reporter driven by the E2F1 promoter. The
luciferase assays showed that the exogenous E2F1 pro-
moter activity was reduced threefold upon PAX8
knockdown (Figure 4c). This indicates a requirement
for PAX8 in regulating basal E2F1 gene expression.
Next, to determine whether PAX8 directly transacti-
vates the E2F1 promoter we investigated the E2F1
promoter for regulation by PAX8 protein through direct
binding to the endogenous promoter. PAX8 putative
binding sites were identiﬁed using a web-based promoter
analysis tool, ConTra (Hooghe et al., 2008; Figure 4d).
To determine whether PAX8 is recruited to these sites,
chromatin immunoprecipitation (ChIP) assays were
performed using an anti-PAX8 antibody, followed by
qPCR analysis using site-speciﬁc primers. A region
Figure 3 Depletion of PAX8 induces cell-cycle arrest through
inhibition of DNA synthesis. (a) A498 and 786-O cells were
transfected with the indicated siRNA. The cells were subjected to
BrdU incorporation assays at 48h post transfection (as described
under Materials and methods). The percentage of cells in each cell-
cycle phase is shown. (b) Experimental design for measuring
S-phase progression using BrdU pulse–chase labeling assay.
siRNA-transfected A498 and 786-O cells were pulse-labeled for
15min with BrdU at 48h post transfection. The S-phase cell
population was monitored 24h after pulse labeling. (c) FACS
proﬁles for the indicated samples. Percentages of total cells with
BrdU incorporated (R1, gray) and cells in S-phase (R2, black) were
estimated. The data are the means±s.e.m. of three indepen-
dent experiments. BrdU, 5-bromodeoxyuridine; siRNA, small
interfering RNA.
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Oncogenewithout a putative PAX8-binding site (Site-C) was
selected as the calibrator to calculate relative fold
enrichment. The ChIP–qPCR results revealed a sig-
niﬁcant relative fold enrichment of PAX8 binding to the
Site-2 region (7.5-fold, Po0.01) relative to the control
site (Site-C), which has no putative PAX8-binding site
(Figure 4d). Interestingly, this region containing Site-2
has also been shown to be enriched in Myc-immuno-
precipitated chromatin (Leung et al., 2008). Collectively,
these data support the hypothesis that E2F1 is a novel
PAX8 target gene.
PAX8 and RB function together in mediating
E2F1 transcription
As seen above, PAX8 is required for E2F1 gene
expression. It is well documented that E2F1 transcriptional
activity is tightly regulated by RB through the formation
of a complex of RB and E2F1 proteins. Furthermore, RB
has been demonstrated to funct i o na saP A X 8t r a n s c r i p -
tional co-activator in regulating gene expression in the
thyroid (Miccadei et al.,2 0 0 5 ) .T h e r e f o r e ,i ti sp o s s i b l e
that RB is involved in the PAX8-mediated regulation of
E2F1 expression. To investigate this possibility, we initially
studied the RB transcript level following PAX8 knock-
down using A498 and 786-O cells. qPCR analysis revealed
no substantial changes in RB mRNA levels following
PAX8 silencing (Figure 5a). Next, we examined RB
protein level in the PAX8-depleted cells using multiple
cancer cell lines. Surprisingly, the RB protein level was
markedly depleted with the loss of PAX8 (Figure 5b),
suggesting that the RB protein was destabilized in the
absence of PAX8. The destablization effect was also
observed when RB was constitutively expressed (pCMV-
RB; compare the ﬁrst, the second and the third lanes;
Figure 5c). Further experiments with the proteasome
inhibitor (MG132) indicated that RB depletion in PAX8
knockdown cells was dependent on proteasomal degrada-
tion. Treatment of PAX8-depleted cells (K1) with MG132
caused an accumulation of RB (compare the second and
the fourth lane; Figure 5c). Furthermore, the requirement
of PAX8 for RB stability was also conﬁrmed when
exogenous RB expression was shown to behave in a
manner similar to that of endogenous RB (compare the
third and ﬁfth lanes; Figure 5c).
Co-occupancy of PAX8 and RB on a thyroid-speciﬁc
gene promoter has been demonstrated collectively using
Figure 4 PAX8 directly regulates E2F1 expression through stimulation of E2F1 promoter activity. The effects of PAX8 knockdown
on the expression of E2F1 targets, including E2F1 itself, were analyzed at (a) the transcript and (b) the protein level. (a) Total RNA
was isolated from the indicated sample at 48h post transfection and subjected to qPCR analysis. Gene expression levels were
normalized to the expression of the housekeeping genes, PPIB and YWHAZ, and presented relative to the siControl-transfected
samples. The data are means±s.d. of three independent experiments. (b) Whole-cell lysates were extracted from siRNA-transfected
A498, 786-O, IGROV-1 and K1 cells at 96h post transfection. The lysates were subjected to immunoblotting using the indicated
antibodies. (c) Effect of PAX8 knockdown on E2F1 promoter activity was assessed using luciferase assay. At 24h post siRNA
transfection, K1 cells were co-transfected with the indicated luciferase-promoter plasmid and pCMV-b-gal plasmid. Relative luciferase
units (RLUs) are normalized to b-gal activity. (d) The promoter sequence of pE2F1-Luc was analyzed using the ConTra web tool. Site-
speciﬁc primers were designed and used for ChIP–qPCR ampliﬁcation for each putative PAX8-binding site (Sites-1 to -5). A region
without any putative PAX8-binding site (Site-C) was used as the negative control. A498 cells were subjected to ChIP using a PAX8
antibody. IP chromatin was analyzed by ChIP–qPCR using site-speciﬁc primers. Fold enrichment is shown relative to Site-C (¼1.0).
Statistical signiﬁcance was assessed using one-way analysis of variance; **Po0.01. The data shown in panels c and d are the
means±s.e.m. of three and two independent experiments, respectively. ChIP, chromatin immunoprecipitation; IP, immunoprecipi-
tation; qPCR, quantitative PCR; siRNA, small interfering RNA.
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Oncogeneluciferase promoter–reporter assays, ChIP analyses and
co-IP in rat thyroid cells (Miccadei et al., 2005). On the
basis of these previous ﬁndings, we speculated that RB
could also function as a cofactor in PAX8-mediated
E2F1 transcription. Therefore, we sequentially trans-
fected siRNAs targeting RB, followed 24h later by co-
transfection with a Pax8 expression construct and the
E2F1 promoter luciferase reporter into K1 thyroid
cancer cells. Validation of the knockdown and over-
expression is shown in Supplementary Figure S2. The
luciferase assays revealed that transactivation of the
E2F1 promoter by Pax8 (2.4-fold) was enhanced in the
absence of RB (4.1-fold; Figure 6a). Collectively, these
data demonstrate that RB represses Pax8-mediated
E2F1 transcription in thyroid cancer cells.
To determine whether coregulation of the E2F1
promoter by PAX8/RB also occurs in RCC cell lines,
we ﬁrst performed coimmunoprecipitation (Co-IP) to
demonstrate an in vivo interaction between endogenous
PAX8 and RB in A498 RCC cells. Endogenous RB was
immunoprecipitated followed by immunoblotting with
PAX8 antibody (Figure 6b), conﬁrming the formation
of the PAX8–RB complex in RCC cells. Next, we asked
whether regulation of the E2F1 promoter by PAX8/RB
is due to co-occupancy of RB on the same PAX8-
binding site (Site-2). We performed ChIP assays using
an antibody against RB and used primers speciﬁc for the
Site-1 region as the positive control. This region
contains the E2F1-binding site (Johnson et al., 1994),
which was shown to be enriched in RB-immunopreci-
pitated chromatin (Wells et al., 2003). The results
showed that the PAX8-binding site (Site-2) was sig-
niﬁcantly enriched in the RB-immunoprecipitated chro-
matin as compared with that in the negative control
Site-C (Po0.05). Similarly, the positive control, Site-1,
was also enriched, as expected (Site-2, 4.7-fold; Site-1,
4.2-fold; Site-C 2.0-fold; Figure 6c). These ﬁndings
suggest that RB is recruited to the PAX8-binding site
and is involved in PAX8-mediated E2F1 transcription in
RCC cells. Together, our results demonstrate that PAX8
Figure 5 PAX8 is required for RB protein stability. The effect of
PAX8 knockdown on RB expression at (a) the transcript and (b)
the protein levels. (a) Total RNA was isolated from the indicated
sample at 48h post-transfection, and subjected to qPCR analysis.
Gene expression levels were normalized to the expression of the
housekeeping genes, PPIB and YWHAZ, and presented relative to
the siControl-transfected samples. The data are means±s.d. of
three independent experiments. (b) Whole-cell lysates were
extracted from siRNA-transfected A498, 786-O, IGROV-1 and
K1 cells at 96h post transfection. The lysates were subjected to
immunoblotting using the indicated antibodies. (c) Effects of
proteasome inhibition on RB depletion in response to PAX8
knockdown. K1 cells were transfected with the indicated siRNA.
After 24h, cells were transfected either with a vector control ( )o r
with pCMV-RB (þ). At 48h post DNA transfection, the cells were
incubated in medium with or without MG132 for 12h. Whole-cell
lysates were then extracted and subjected to immunoblotting using
the indicated antibodies. qPCR, quantitative PCR; RB, retino-
blastoma; siRNA, small interfering RNA.
Figure 6 PAX8 and RB co-occupy the E2F1 promoter and
function antagonistically in regulating E2F1 promoter activity.
(a) The effect of RB knockdown on the PAX8 transactivation of
E2F1 promoter activity. At 24h post-siRNA transfection, K1 cells
were co-transfected with either vector control or pCMV-Pax8, as
well as the indicated luciferase-promoter plasmid and the pCMV-b-
gal plasmid. The relative luciferase units (RLUs) are normalized
to b-gal activity. (b) A498 whole-cell lysate was subjected to IP
using an RB antibody. IP protein complexes were analyzed using
immunoblotting (IB) to detect RB and PAX8 proteins. NS
indicates IP using a nonspeciﬁc antibody. (c) A498 cells were
subjected to ChIP using a PAX8 antibody. IP chromatin was
analyzed by ChIP–qPCR, using primers targeting the putative
PAX8-binding site (Site-2). In addition, Site-1, which contains the
characterized RB-E2F1-binding site, was used as a positive control.
The negative control Site-C was used for comparison. Fold
enrichment is shown relative to the negative control site (Site-C).
Statistical signiﬁcance was assessed using unpaired Student’s
t-test; *Po0.05. Data for a and c are the means±s.e.m. of three
independent experiments for each panel. ChIP, chromatin im-
munoprecipitation; IP, immunoprecipitation; qPCR, quantitative
PCR; RB, retinoblastoma; siRNA, small interfering RNA.
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Oncogeneis required for RB stabilization, and together with RB,
regulates E2F1 expression in the cell-cycle control-
regulatory pathway.
Discussion
Here we describe a new role for PAX8 expression in
human tumor cell lines, with implications for under-
standing the mechanisms of tumor-associated growth
regulation. We show that the developmental transcrip-
tion factor, PAX8, which is frequently expressed in
human tumors, is capable of promoting tumor cell
growth through direct regulation of the E2F1 promoter
and upregulation of E2F1 expression. Regulation of
both E2F1 levels and RB stability by PAX8 in tumor
cells might be a reﬂection of mechanisms controlling
cell-cycle progression and exit upon terminal differentia-
tion in normal cells, except that in tumor cells there is a
failure of the normal processes to turn PAX8 expression
off, which may be important to understand why the
tumor cells never terminally differentiate. However, it is
paradoxical that PAX8 also promotes RB protein
stability, as it seems that PAX8 simultaneously regulates
a function that opposes the facilitation of E2F1
expression in tumor cell lines, as RB is known to inhibit
the role of E2F1 (Dyson, 1998). We propose a model
below to potentially explain the function of PAX8 in
tumor cells, which may help to resolve the paradox.
Brieﬂy, the key points of our model (Figure 7) are as
follows: in cells that normally express PAX8, PAX8
drives basal levels of E2F1. Meanwhile, hypopho-
sphorylated RB binds to E2F1 and prevents transcrip-
tional activation of cell-cycle regulatory genes. We
propose that this PAX8-mediated E2F1 regulation could
be essential for maintaining the cell’s potential to
respond to cell proliferation signals before S-phase
entry. The tightly restricted basal E2F1 protein level
hence serves as ‘standby’ E2F1 to form a complex with
RB. However, PAX8 also interacts with RB and it
stabilizes RB protein levels, which then form a negative
feedback loop to modulate PAX8-mediated E2F1
expression. Upon G1/S transition, RB is phosphorylated
in order to release free E2F1 (Chellappan et al., 1991;
Burkhart and Sage, 2008). E2F1 then autoregulates its
own promoter to maximize the cellular E2F1 level,
which thereby activates the gene expression required for
S-phase entry (Johnson et al., 1994). In tumor cell
lines with persistently high levels of PAX8 expression,
the PAX8–RB complex is also able to bind to and
transactivate the E2F1 promoter. However, where the
RB protein has been targeted for proteasomal degrada-
tion, or where the RB gene is silenced or mutated, both
E2F1 and PAX8 are released from RB, and transactiva-
tion of the E2F1 promoter by PAX8 alone is stronger
than transactivation by the PAX8–RB complex, which
provides an additional competitive advantage to tumor
cells in which RB loss has occurred. If PAX8 is silenced,
the E2F1 promoter is deactivated. The basal ‘standby’
levels of E2F1 disappear, RB is no longer required to
control E2F1 expression and therefore it is targeted for
proteasomal degradation. The acute loss of both E2F1
and RB through PAX8 silencing creates cellular stress
that eventually induces senescence.
Members of the PAX gene family encode important
regulators of embryogenesis (Dahl et al., 1997). PAX2
and PAX8, however, have overlapping functions and
exhibit redundancy in kidney development (Bouchard
et al., 2002). Knockout mutations of both Pax2 and
Pax8 together are necessary and sufﬁcient to entirely
eliminate the nephric lineage (Bouchard et al., 2002).
Whereas PAX2 expression diminishes in adult kidneys
(Daniel et al., 2001), PAX8 expression persists (Tong
et al., 2009). The role of PAX8 expression in adult
kidney has not yet been explored, but our immunohis-
tochemical localization of PAX8 expression in adult
kidney to regions of putative renal stem cell niches
(reviewed in Little and Bertram (2009)) suggests that the
role of PAX8 in renal stem cells should be investigated
further. PAX2 and PAX8 are both frequently expressed
in kidney tumors, including Wilms tumors, and in renal
cell carcinomas (Eccles et al., 1995; Daniel et al., 2001;
Tong et al., 2006, 2009). The silencing of PAX2 in
kidney tumor cell lines has been previously reported to
decrease tumor cell growth and survival (Hueber et al.,
2006). In comparison, PAX8 has been suggested to be
required for the maintenance of hTERT and hTR
expression in low-grade gliomas (Chen et al., 2008).
Human cancers frequently acquire alterations in the
RB–E2F1 network (Burkhart and Sage, 2008). How-
ever, recent studies show that loss of RB function can
lead to centromere dysfunction, chromosome instability
(Manning et al., 2010) and inappropriate DNA synth-
esis in oncoprotein-expressing cells, which would
otherwise become senescent through oncogene over-
expression (Peeper et al., 2001; Sage et al., 2003). During
tumor progression, and before the loss of RB function in
tumor cells, PAX8-mediated stabilization of RB protein
and simultaneous maintenance of E2F1 expression
could maintain responsiveness to proliferation signals
in cancer cells at the early stages of tumor development,
particularly if RB loss leads to centromere dysfunction
and chromosome instability, as these malfunctions may
Figure 7 A model of the effect of PAX8 regulation on RB and
E2F1 expression. PAX8 positively regulates both RB and E2F1
expression through different mechanisms. PAX8 binds to the E2F1
promoter, thereby transcriptionally activating E2F1 expression. In
comparison, interaction of PAX8 with RB stabilizes the RB
protein, which then forms a negative feedback loop, restricting
PAX8-mediated E2F1 expression. We propose that this PAX8-
mediated E2F1 regulation could be essential to maintain cell
proliferation signal before S-phase entry. RB, retinoblastoma.
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At later stages upon RB loss, increased levels of E2F1
generated by persistent PAX8 expression may contri-
bute to a senescence by-pass mechanism operating
during tumorigenesis. Much later, if/when loss of RB
has occurred and multiple oncogenic pathways have
been activated, the continued expression of PAX8 may
then no longer be required, and a gradual loss of PAX8
expression might then be expected. Although a gain of
function has been implicated for PAX8 expression in
cancer, intriguingly, a gradual loss of PAX8 expression
indeed does seem to correlate with the malignant growth
of higher-grade tumors, especially in thyroid and pancreatic
tumors (Zhang et al., 2006; Long et al.,2 0 1 0 ) .T h e
oncoprotein, Myc, has also been demonstrated to have a
role in maintaining the pre-S-phase E2F1 level (Leung
et al., 2008), and interestingly, the proposed Myc-binding
site is immediately adjacent to the PAX8-binding site
identiﬁed in this study (Leung et al., 2008), suggesting that
there could be potential for complex formation between
PAX8 and Myc in regulating E2F1 transcription. Although
Myc expression was shown to be cell-cycle dependent
(peaks in the G1 phase; Kelly et al.,1 9 8 3 ) ,P A X 8
expression seems to be cell-cycle independent (data not
shown). However, this is perhaps not surprising, as PAX8
is responsible for regulating the gene expression required
for other cellular processes such as differentiation.
Our results have largely been derived from cancer cell
lines. However, the generality of the effect that PAX8
silencing has on senescence, cell-cycle control and E2F1
transcription in multiple cancer types suggests that this is a
common non-redundant function of PAX8 expression in
cancer. In contrast, PAX2 silencing does not produce a
similar effect as the silencing of PAX8, even though PAX2
and PAX8 are often co-expressed in cancer cells. Whether
the roles that we have described for PAX8 in cancer cells
also apply to developing cells is presently unclear, although
several studies have shown that RB is vital for the
maintenance of cellular homeostasis through coordination
of proliferation and differentiation in normal cells (Skapek
et al., 2006). Additional investigations are presently under
way to characterize the interactions between PAX2 and
PAX8 in cancer and normal cells.
Materials and methods
Cell culture
ACHN, CAKI-1, 786-O, 769-P, RXF-393, TK-10, UO-31,
J82, Y79, WERI-Rb, IGROV-1 and SKOV-3 cells were grown
in RPMI medium (Invitrogen, Carlsbad, CA, USA). A498, EJ,
T24, K1 (a gift from D Wynford-Thomas) (Wyllie et al., 1999),
MCF-7, PC-3 and RKO cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (Invitrogen). Both media were
supplemented with 10% fetal bovine serum (BioInternational,
Auckland, New Zealand). All cells were incubated at 371C
under 5% CO2 in a humidiﬁed incubator.
siRNA, plasmids and antibodies
Two siRNAs targeting PAX8 were used: the SMARTpool
ON-TARGETplus siPAX8 (siPAX8-1, L-003778-00; Dharmacon,
Lafayette, CO, USA) and the Silencer Pre-designed siPAX8
(siPAX8-2, 114354; Ambion, Austin, TX, USA). SiRNA-
targeting RB, the SMARTpool ON-TARGETplus siRB
(L-003296-00) and the SMARTpool ON-TARGETplus
siControl non-targeting pool (D-001810-10) were purchased
from Dharmacon. The expression plasmids used were pCMV-
RB (a gift from S Hsu and E Harlow; Hsu et al., 2001) and
pCMV-Pax8 (a gift from R Di Lauro). pCR3.1 (Invitrogen)
was used as a ‘ﬁller’ to maintain equal total amounts of
plasmid DNA transfected. The promoter–luciferase reporter
constructs used were pE2F1-Luc, containing an E2F1-ﬂanking
sequence from  728/þ70 (a gift from K Ohtani) (Johnson
et al., 1994), and pGL2-basic (Promega, Madison, WI, USA).
pCMV-b-gal was a gift from P Daniel. The antibodies used in
immunohistochemistry, immunoblotting and IP were PAX8
(PA 0300; Biopat, Milan, Italy), b-tubulin (E7; developed by
M Klymkowsky, Developmental Studies Hybridoma Bank),
E2F1 (sc-193; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), cyclin-A (611268; BD Pharmingen, San Jose, CA,
USA), CDC6 (sc-9964; Santa Cruz Biotechnology), b-actin
(ab6276; Abcam, Cambridge, MA, USA), RB (for immuno-
blotting–554136, BD Pharmingen; for IP–sc-50, Santa Cruz
Biotechnology) and CD40 (sc-975; Santa Cruz Biotechnology).
siRNA and DNA transfection
Cells were plated (to obtain 30% conﬂuence the following day)
and reverse-transfected with 10nM siRNA using Lipofecta-
mine RNAiMAX (Invitrogen) according to the manufacturer’s
instructions. After transfection, the cells were harvested and
processed as described in the ﬁgure legends. For siRNA and
plasmid co-transfection, cells were ﬁrst transfected with
siRNA as described above. Twenty-four hours after siRNA
transfection, the cells were transfected with the indicated
plasmid construct using FuGENE-6 (Roche, Indianapolis, IN,
USA) according to the manufacturer’s instructions. The
amount of plasmid constructs transfected is described for each
experiment as follows.
Analysis of cell growth and senescence
For growth analysis, the number of viable cells was determined
using the trypan blue exclusion assay at 48 and 96h post
siRNA transfection. For senescence analysis, cells were
siRNA-transfected as described above and photographed at
120h post transfection using a phase-contrast microscope. For
SA-b-gal staining, at 120h post siRNA transfection, cells were
ﬁxed for 5min (room temperature) in 4% paraformaldehyde,
washed and incubated at 371C with 5-bromo-4-chloro-3-
indolyl b-D-galactopyranoside (1mg/ml) and dissolved in a
solution containing 40mM citric acid (pH 6.0), 5mM potassium
ferrocyanide, 5mM potassium ferricyanide, 150mM NaCl and
2m M MgCl2. After 24h of incubation, stained cultures were
viewed under bright-ﬁeld illumination and photographs were
taken at  10 magniﬁcation. The percentage of SA-b-gal-
positive cells was determined by counting in a blind manner.
Flow cytometry
For quantitation of cells in the G0/G1, S and G2/M phases of
cell cycle, siRNA-transfected cells (described above) were
incubated with BrdU (5mM) at 72h post siRNA transfection
for 15min and harvested. The cells were processed using the
BrdU Flow Kit (BD Pharmingen). For quantitation of cells
progressing through the cell cycle, siRNA-transfected cells
were incubated with BrdU as described above at 48h post
transfection, washed and incubated in culture medium for
another 24h. The S-phase population of cells was then
measured using the BrdU Flow Kit. The ﬂow cytometry
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Oncogeneproﬁles were acquired using a FACS Calibur (Becton
Dickinson). Approximately 10000 cells were analyzed per
sample. All ﬂow cytometry data were analyzed using the
FlowJo software (Tree Star, Ashland, OR, USA).
Quantitative real-time PCR (RT–qPCR)
Total RNA was extracted using the TRIZOL reagent
(Invitrogen) and further puriﬁed with the PureLink RNA
Mini Kit (Invitrogen). A 200-ng sample of total RNA was
reverse-transcribed with the Superscript III Reverse Tran-
scriptase (Invitrogen), using 10mM random hexamer primers
(Roche) for the Superscript Reverse Transcriptase (Invitrogen),
according to the manufacturer’s instructions. qPCR ampliﬁca-
tion was performed with a 7300 real-time PCR system (Applied
Biosystems, Foster City, CA, USA) using the Platinum SYBR
Green qPCR Supermix-UDG with ROX (Invitrogen), using
speciﬁc primers (200nM) as listed in Supplementary Table S2.
In each experiment, the housekeeping genes, PPIB and
YWHAZ, were ampliﬁed as a reference standard for normal-
ization. The expression of each target gene was normalized to
the expression of the housekeeping genes and presented relative
to the corresponding siControl sample.
Immunohistochemistry
RCC tissues and their normal kidney counterparts embedded
in parafﬁn blocks were obtained from Dunedin Hospital with
informed consent for research use. Approval for using archival
specimens was obtained from the New Zealand Multi-Region
Ethics Committee. Immunohistochemical staining was per-
formed as described by He et al. (2010). Sections were stained
using a 3,30-diaminobenzidine chromogen and couterstaining
with hematoxylin. The PAX8 antibody (PA 0300; Biopat) was
used at 1:2000.
Immunoblotting
Cells were trypsinized, washed in phosphate-buffered sali-
ne(PBS) and lysed on ice for 30min. The lysis buffer contained
50mM Tris–HCl (pH 8.0), 150mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 
Complete Mini Protease Inhibitor Mixture (Roche), 1mM
sodium orthovanadate and 1mM phenylmethylsulfonyl ﬂuor-
ide. Whole-cell lysates were centrifuged (16100g for 20min at
41C) and protein quantiﬁcation was carried out using the
colorimetric BCA Protein Assay Kit (Pierce, Rockford, IL,
USA). In all cases, 40mg of the lysates were boiled in the 1 
reducing sample buffer containing 60mM Tris–HCl (pH 6.8),
60mM SDS, 10% glycerol, 5% b-mercaptoethanol and 0.005%
bromophenol blue. The resulting protein samples were then
separated by SDS–PAGE and electroblotted onto nitrocellu-
lose membranes. The membranes were blocked with PBS
containing 2.5% non-fat dried milk and probed overnight with
primary antibodies. The primary antibodies used have been
described earlier. The secondary antibodies used was horse-
radish peroxidase-conjugated goat anti-mouse antibody or
goat anti-rabbit (Sigma, St Louis, MO, USA) antibody.
Signals were visualized using the SuperSignal West Pico
Chemiluminescent Substrate (Pierce).
MG132 treatment
K1 cells were transfected with siRNA and then with DNA
constructs as described earlier. At 72h after siRNA transfec-
tion, the cells were incubated with the proteasome inhibitor
MG132 (20mM; Sigma) for 12h. The cells were collected for
immunoblotting as described above. The total amount of
plasmid constructs transfected was 1mg (per well in a six-well
plate). To overexpress RB, a mixture containing 500ng of
pCMV-RB and 500ng of pCR3.1 was used; 1mg of pCR3.1
was used for negative control.
Reporter assay
K1 cells were reverse-transfected with siRNA (to yield 30%
conﬂuence the following day) and then with DNA constructs
as described earlier. For DNA transfection, the cells were
transfected with a total amount of 250ng of DNA (per well
in a 24-well plate). The DNA mixture contained 100ng of
pE2F1-Luc or pGL2-basic, 100ng of pCMV-Pax8 or pCR3.1
and 50ng pCMV-b-gal. At 48h post DNA transfection, the cells
were lysed and luciferase and b-gal activities were measured
using the Luciferase Assay System (Promega) following the
manufacturer’s instructions. Relative luciferase units were
obtained by normalizing luciferase activities to b-gal.
ChIP and ChIP–qPCR
A498 cells were grown to 90–95% conﬂuence in 10-cm plates.
Four plates were used for each ChIP reaction. Formaldehyde
was added to the culture medium to a ﬁnal concentration of
1% and cross-linking was carried out for 10min at room
temperature. Cross-linking was stopped by adding glycine to a
ﬁnal concentration of 0.125 M. After a 5-min incubation period
at room temperature, the cells were washed in cold PBS and
harvested by scraping cells in 0.75ml sonication buffer (50mM
Tris–HCl (pH 8.0), 10mM EDTA, 1% SDS, 1  Complete
Mini Protease Inhibitor Mixture, 1mM sodium orthovanadate
and 1mM phenylmethylsulfonyl ﬂuoride). The cells were
sonicated 10 times for 15s at 25% amplitude to generate
fragments of B200–850bp. Samples were then centrifuged at
12000g for 10min at 41C and the supernatants (chromatin)
were collected. Chromatin was diluted 2.5 times in dilution
buffer (2mM EDTA, 100mM NaCl, 20mM Tris–HCl (pH 8.0)
and 0.5% Triton X-100). Samples were pre-cleared with
Dynabeads Protein-G (Invitrogen) for 2h at 41C. Pre-cleared
samples were then incubated for 16h with the indicated
antibody (4mg) or without an antibody (mock) as negative
control. Complexes were then recovered by incubating the
samples with 50ml Dynabeads for 4h at 41C. The immuno-
precipitates were then serially washed twice with 1ml of low-
salt wash buffer (2mM EDTA, 20mM Tris–HCl (pH 8.0), 0.1%
SDS, 1% Triton X-100 and 150mM NaCl), high-salt wash
buffer (20mM Tris–HCl (pH 8.0), 2mM EDTA, 0.1% SDS, 1%
Triton X-100 and 500mM NaCl), LiCl wash buffer (10mM
Tris–HCl (pH 8.0), 1mM EDTA, 1% NP-40, 1% deoxycho-
late, 0.25 M LiCl) and then with TE buffer (10mM Tris–HCl
(pH 8.0), 1mM EDTA). Immune complexes were eluted from
the beads by boiling in 50ml Chelex-100 (10% wt/vol),
proteinase-K (20mg) digestion and boiling again as described
by Dahl and Collas (2008). After the ﬁnal boiling step, samples
were centrifuged at 12000 g for 2min at 41C. The eluted ChIP
DNA was collected. A 50-ml volume of sterile distilled water
was added to the mixture, centrifuged and pooled with the ﬁrst
eluted sample. For input DNA, the supernatant from the
negative control sample was precipitated with three volumes of
100% ethanol for 30min at  801C. The precipitated DNA
was collected by centrifugation at 16100 g for 10min at 41C.
The DNA pellet was washed in 70% ethanol, centrifuged and
dried, and then dissolved in 450ml of Chelex-100 overnight at
41C, and puriﬁed as described above.
Equal amount of DNA (50ng) was used for each qPCR.
Primer information is listed in Supplementary Table S3. An
input standard curve dilution series was used for determining
primer ampliﬁcation efﬁciency, which was used for normal-
izing the ChIP-DNA signal to the input DNA signal. The fold
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Oncogeneenrichment for promoter occupancy was calculated using
2(DDCt), where DDCt¼(Ct(IP) Ct(input dilution fac-
tor)) (Ct(mock) Ct(input dilution factor)).
Co-immunoprecipitation
A498 cells were grown to 90–95% conﬂuence in 10-cm plates.
Four plates were used for each IP reaction. IP was performed
using the protocol from Zhang et al. (2007), with modiﬁcations.
The cells were washed in cold PBS twice and collected by
scraping. The cell suspension was centrifuged at 300 g for 10min
at 41C. Cells were resuspended in cold PBS containing 10nM
dimethyl pimelimidate.2 HCl (DMP) to crosslink the cellular
proteins. Crosslinking was performed at 41Cf o r2 ha n d
terminated with 50mM Tris–HCl (pH 8.0) at room temperature
for 15min. The cell suspension was centrifuged as described
before and lysed using the immunoblotting lysis buffer. IP was
performed as described for ChIP. A sample incubated with an
unrelated antibody (anti-CD40) was used as negative control.
Immune complexes were recovered using Dynabeads as
described above and eluted by boiling the beads in
1  reducing sample buffer. Immunoblotting was performed
as described, with the following modiﬁcations. Instead of using
a horseradish peroxidase-conjugated secondary antibody,
membranes were incubated with the Clean-Blot IP Detection
Reagent (Pierce), diluted at 1:200, for 3h at room temperature
to avoid interference from IgH.
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